1600 Huron Parkway
Ann Arbor, MI 48109
Available to mentor
Dr. Rehemtulla has over 25 years of research experience in the field of oncogenic signaling in cancer as well as development and evaluation of inhibitors for these signaling pathways as anticancer therapies. He has developed technologies that enable non-invasive imaging of signaling pathways in cells as well as in mouse models of cancer. These technologies have been leveraged for the discovery of novel drugs that target oncogenic pathways and have antitumor activity. He has also utilized the ability to monitor signaling pathways in live cells to identify previously unappreciated signaling hubs that mediate the transformed phenotype.
-
Center MemberRogel Cancer Center
Combining small molecules that inhibit oncogenic pathways with ionizing radiation to improve the efficacy of radiation therapy in brain and pancreatic cancer. Specifically, he is evaluating agents that target the cellular DNA damage response as radiation sensitizers.
Signaling pathways that mediate therapeutic resistance in brain tumors.
Pathways that enhance the capacity of tumor cells to tolerate radiation therapy by enhancing the capacity to repair damaged DNA are being investigated for therapeutic intervention to restore sensitivity to radiation.
-
Chan SM, Raglow Z, Pal A, Gitlin SD, Legendre M, Thomas D, Mehta RK, Tan M, Nyati MK, Rehemtulla A, Markovitz DM. 2024 Mar 20;PreprintA molecularly engineered lectin destroys EGFR and inhibits the growth of non-small cell lung cancer.
DOI:10.1101/2024.03.18.585535 PMID: 38562773 -
Shankar S, Ravikumar V, Tripathy A, Ji S, Loper J, Hassan Z, Fehmi Z, Haydin Y, Huang D-L, Bhadury S, Kulkarni R, Regier J, Wahl D, Rao A, Rehemtulla A, Al-Holou WN. Cancer Research, 2024 Mar 4; 84 (5_Supplement_1): b001 - b001.Journal ArticleAbstract B001: Glioblastoma evolution and resistance is mediated by a shift in cell state and tumor microenvironmental interactions
DOI:10.1158/1538-7445.brain23-b001 -
Ravikumar V, Shankar S, Ji S, Hassan Z, Haydin Y, Huang D-L, Fehmi Z, Rehemtulla A, Rao A, Al-holou W. Neuro-Oncology, 2023 Nov 10; 25 (Supplement_5): v288 - v288.Journal ArticleTMIC-44. THY1 CONFERS PROLIFERATIVE ADVANTAGES AND THERAPY RESISTANCE WITHIN LOCALIZED NICHES OF GLIOMA
DOI:10.1093/neuonc/noad179.1110 -
Stansbury CM, Dotson GA, Pugh H, Rehemtulla A, Rajapakse I, Muir LA. JCI Insight, 2023 Oct 9; 8 (19): e171701Journal ArticleA lipid-associated macrophage lineage rewires the spatial landscape of adipose tissue in early obesity
DOI:10.1172/jci.insight.171701 -
Ram S, Tang W, Bell AJ, Pal R, Spencer C, Buschhaus A, Hatt CR, diMagliano MP, Rehemtulla A, Rodríguez JJ, Galban S, Galban CJ. Neoplasia, 2023 Aug; 42: 100911Journal ArticleLung cancer lesion detection in histopathology images using graph-based sparse PCA network.
DOI:10.1016/j.neo.2023.100911 PMID: 37269818 -
Stansbury CM, Dotson GA, Pugh H, Rehemtulla A, Rajapakse I, Muir LA. JCI Insight, 2023 Oct 9; 8 (19):Journal ArticleA lipid-associated macrophage lineage rewires the spatial landscape of adipose tissue in early obesity.
DOI:10.1172/jci.insight.171701 PMID: 37651193 -
Awadia S, Sitto M, Ram S, Ji W, Liu Y, Damani R, Ray D, Lawrence TS, Galban CJ, Cappell SD, Rehemtulla A. J Biol Chem, 2023 Jun; 299 (6): 104786Journal ArticleThe adapter protein FADD provides an alternate pathway for entry into the cell cycle by regulating APC/C-Cdh1 E3 ubiquitin ligase activity.
DOI:10.1016/j.jbc.2023.104786 PMID: 37146968 -
Shankar S, Ravikumar V, Wang H, Ji S, Hasan Z, Fehmi Z, Haydin Y, Wahl DR, Rao A, Rehemtulla A, Al-Holou W. Cancer Research, 2023 Apr 4; 83 (7_Supplement): 3909 - 3909.Proceeding / Abstract / PosterAbstract 3909: THY1 regulates therapy resistance in glioblastoma recurrence
DOI:10.1158/1538-7445.am2023-3909